Abstract
BackgroundImmunotherapy, particularly immune checkpoint inhibitors, has improved the effectiveness of NSCLC treatment. However, as not all patients benefit from them, identifying predictive biomarkers could be highly valuable in guiding immunotherapy...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
